Keyphrases
Anchorage-independent Growth
9%
Anti-HER2 Antibody
9%
Breast Cancer Cells
100%
Breast Tumor
18%
Cancer Cells
9%
ErbB
9%
Growth Hormone Receptor
9%
Growth Inhibition
9%
HER2 Overexpression
27%
Herceptin
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Induced Growth
9%
Inhibitory Effect
9%
Ligand-receptor Binding
100%
MCF7 Breast Cancer Cells
9%
Non-tumor Tissue
9%
Novel Therapeutics
9%
Partial Inhibition
9%
Peroxisome Proliferator-activated Receptor
100%
Receptor 2
9%
Receptor Expression
100%
Receptor Sensitivity
100%
Receptor-interacting Protein Kinase 1 (RIPK1)
9%
Terminal Differentiation
9%
Therapeutic Target
9%
Transcription Factor
9%
Transcriptional Activity
9%
Troglitazone
27%
Biochemistry, Genetics and Molecular Biology
Anchorage Independent Growth
9%
Cancer Cell
100%
Downregulation
9%
Growth Factor Receptor
9%
Growth Inhibition
9%
Messenger RNA
9%
Monoclonal Antibody
9%
Peroxisome Proliferator-Activated Receptor
100%
Sensitization
9%
Transcription Factors
9%
Trastuzumab
9%
Troglitazone
27%
Upregulation
9%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Breast Tumor
18%
Growth Factor Receptor
9%
Malignant Neoplasm
18%
Monoclonal Antibody
9%
Peroxisome Proliferator Activated Receptor
100%
Receptor Protein
9%
Transcription Factors
9%
Trastuzumab
9%
Troglitazone
27%
Immunology and Microbiology
Anchorage Independent Growth
9%
Cancer Cell
100%
Downregulation
9%
Growth Factor
9%
Growth Inhibition
9%
Monoclonal Antibody
9%
Peroxisome
100%
Sensitization
9%
Transcription Factors
9%
Trastuzumab
9%
Upregulation
9%